Phase 0 of 18F FPM Using PET/CT in Patients With a Variety of Malignancies

A Phase 0 Exploratory Microdosing Study of S-(3-18Ffluoropropyl)Homocysteine Hydrochloride; 18FFPM Using PET/CT in Patients With a Variety of Malignancies.

The purpose of this study is to investigate the safety and potential effectiveness of the imaging compound 18F FPM for finding sites of malignancies.

Inclusion Criteria:

• Written informed consent obtained prior to any protocol-specific procedures
• Male and female patients with histologically confirmed squamous cell carcinoma
• At least one site of active malignancy, as demonstrated on the pre-study 18F FDG PET/CT scan performed as part of routine clinical care
• Age >/= 18 years
• Life expectancy >/= 3 months
• ECOG Performance score of 0-2

Exclusion Criteria:

• Pregnant or breastfeeding females
• Systemic anti-neoplastic therapy within the 2 weeks prior to the pre-study 18F FDG PET/CT scan until after the 18F FPM PET/CT scan
• Any serious medical condition which the investigator feels may interfere with the procedures or evaluations of the study
• Patients unwilling or unable to comply with protocol or with a history of non-compliance or inability to grant informed consent